JP2019513761A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513761A5
JP2019513761A5 JP2018553102A JP2018553102A JP2019513761A5 JP 2019513761 A5 JP2019513761 A5 JP 2019513761A5 JP 2018553102 A JP2018553102 A JP 2018553102A JP 2018553102 A JP2018553102 A JP 2018553102A JP 2019513761 A5 JP2019513761 A5 JP 2019513761A5
Authority
JP
Japan
Prior art keywords
fibrosis
pharmaceutical composition
composition according
cholangitis
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018553102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513761A (ja
JP6894923B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/055878 external-priority patent/WO2017178172A1/en
Publication of JP2019513761A publication Critical patent/JP2019513761A/ja
Publication of JP2019513761A5 publication Critical patent/JP2019513761A5/ja
Application granted granted Critical
Publication of JP6894923B2 publication Critical patent/JP6894923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018553102A 2016-04-11 2017-03-13 胆汁うっ滞性及び線維性の疾患の処置方法 Active JP6894923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305425.7 2016-04-11
EP16305425 2016-04-11
PCT/EP2017/055878 WO2017178172A1 (en) 2016-04-11 2017-03-13 Methods of treatment for cholestatic and fibrotic diseases

Publications (3)

Publication Number Publication Date
JP2019513761A JP2019513761A (ja) 2019-05-30
JP2019513761A5 true JP2019513761A5 (https=) 2020-03-26
JP6894923B2 JP6894923B2 (ja) 2021-06-30

Family

ID=55755536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553102A Active JP6894923B2 (ja) 2016-04-11 2017-03-13 胆汁うっ滞性及び線維性の疾患の処置方法

Country Status (23)

Country Link
US (7) US20170290812A1 (https=)
EP (3) EP3777854B1 (https=)
JP (1) JP6894923B2 (https=)
KR (1) KR102431257B1 (https=)
CN (1) CN109069648B (https=)
AU (1) AU2017249602B2 (https=)
DK (2) DK3777855T3 (https=)
EA (2) EA201892298A1 (https=)
ES (3) ES2935185T3 (https=)
HR (1) HRP20201954T1 (https=)
HU (2) HUE052886T2 (https=)
IL (1) IL262052B (https=)
LT (1) LT3442580T (https=)
MD (1) MD3442580T2 (https=)
MX (1) MX384261B (https=)
MY (1) MY195437A (https=)
PH (1) PH12018502142B1 (https=)
PL (1) PL3442580T3 (https=)
PT (2) PT3442580T (https=)
SG (2) SG11201808402RA (https=)
SI (1) SI3442580T1 (https=)
WO (1) WO2017178172A1 (https=)
ZA (1) ZA201807389B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィGenfit 胆汁うっ滞性及び線維性の疾患の処置方法
JP2019513762A (ja) * 2016-04-11 2019-05-30 ジェンフィGenfit 胆汁うっ滞及び線維症の処置方法
WO2018167103A1 (en) 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
BR112019019519A2 (pt) * 2017-03-21 2020-04-22 Novalead Pharma Inc agente terapêutico para a inibição de fosfodiesterase e seus distúrbios relacionados
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター,ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための[2-[(5-ニトロ-1,3-チアゾール-2-イル)カルバモイル]フェニル]エタノエート
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
JP7631217B2 (ja) 2019-04-10 2025-02-18 ジェンフィット 式(i)の化合物及びglp-1受容体アゴニストを含む組合せ療法
CA3130518A1 (en) * 2019-04-12 2020-10-15 Nicolas STANKOVIC-VALENTIN Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
JP7741800B2 (ja) 2019-10-28 2025-09-18 ジェンフィット 抗酸化性質を有する併用療法
CN113398125B (zh) * 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
KR20230110284A (ko) * 2020-11-17 2023-07-21 장피트 간부전 치료 방법
CN116507343A (zh) * 2020-11-17 2023-07-28 基恩菲特公司 治疗肝衰竭的方法
CN115197164B (zh) * 2021-04-12 2025-04-01 杜心赟 新型噻唑类化合物及其制备方法和用途
AU2022271607A1 (en) * 2021-05-11 2023-10-26 Genfit Nitazoxanide in the treatment of sepsis
CN116077502B (zh) * 2021-11-05 2025-12-23 广州医科大学附属妇女儿童医疗中心 叶酸在预防、诊断和治疗胆道闭锁中的应用
AU2023355753A1 (en) * 2022-10-04 2025-04-03 Genfit Nitazoxanide for the treatment of hepatic impairment
CN116911513B (zh) * 2023-02-07 2024-07-26 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
WO2025063816A1 (ko) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 자궁 섬유화증 치료용 조성물
CN117838690B (zh) * 2023-10-09 2024-09-13 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
WO2002051442A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1971594A2 (en) 2005-11-21 2008-09-24 Biogen Idec MA Inc. Substituted pyrazalones
CA2636527C (en) * 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Clostridium propionicum 유래의프로피오닐―CoA 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
EP2408449A4 (en) * 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
NZ596538A (en) 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
KR101961601B1 (ko) 2009-11-16 2019-03-25 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 감염 치료를 위한 2'―플루오로―6'―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
AU2011323682B2 (en) 2010-11-01 2016-06-23 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
EP2680859B1 (en) 2011-03-02 2022-04-27 Jerome Schentag Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
MX2017006083A (es) 2014-11-11 2017-11-08 Romark Laboratories Lc Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
US20190070154A1 (en) 2015-06-24 2019-03-07 Duke University New methods of use for an anti-diarrhea agent
KR102410951B1 (ko) 2016-04-11 2022-06-20 장피트 담즙정체성 및 섬유증 질환의 치료 방법
JP2019513762A (ja) 2016-04-11 2019-05-30 ジェンフィGenfit 胆汁うっ滞及び線維症の処置方法
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィGenfit 胆汁うっ滞性及び線維性の疾患の処置方法

Similar Documents

Publication Publication Date Title
JP2019513761A5 (https=)
D’Alessio et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study
HRP20201954T1 (hr) Metode liječenja kolestatskih i fibrotičnih bolesti
ES2768614T3 (es) Formulaciones de anticuerpos anti-PDL1
ES2765657T3 (es) Formulación farmacéutica de bevacizumab
Strazzabosco et al. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium
US20160146844A1 (en) Compositions and methods for binding lysophosphatidic acid
Allanore et al. Systemic sclerosis: an update in 2008
JP2017113019A5 (https=)
JP2011057695A (ja) 呼吸器の症状を治療又は予防する方法
JP2020535225A5 (https=)
JP2015506944A5 (https=)
Comeglio et al. Beneficial effects of bile acid receptor agonists in pulmonary disease models
JP2017536380A5 (https=)
JP2017141225A5 (https=)
Bou et al. Treatment of uveitis associated with juvenile idiopathic arthritis
RU2017122758A (ru) Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций
TW200812589A (en) Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
US20100247538A1 (en) IL-18 and Protein Kinase R Inhibition for the Treatment of COPD
JP2018524274A5 (https=)
US20060121043A1 (en) Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
WO2017125502A1 (en) Substance that inhibits p2y12 receptor, for use in the preventive treatment of systemic sclerosis in patients with raynaud's phenomenon and a dysimmunity
Boratyńska et al. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients
JP2016050181A (ja) 血管炎治療剤
NZ746668B2 (en) Methods of treatment for cholestatic and fibrotic diseases